TASSINARI, ELISA
 Distribuzione geografica
Continente #
EU - Europa 146
NA - Nord America 70
AS - Asia 22
AF - Africa 12
Totale 250
Nazione #
IT - Italia 72
US - Stati Uniti d'America 68
SE - Svezia 16
CH - Svizzera 13
CI - Costa d'Avorio 12
IE - Irlanda 12
JO - Giordania 12
BG - Bulgaria 11
FI - Finlandia 10
NL - Olanda 4
CN - Cina 3
FR - Francia 3
CA - Canada 2
HK - Hong Kong 2
IN - India 2
PK - Pakistan 2
PL - Polonia 2
RU - Federazione Russa 2
AT - Austria 1
JP - Giappone 1
Totale 250
Città #
Bologna 19
Abidjan 12
Amman 12
Ashburn 12
Bern 12
Dublin 12
Sofia 11
Helsinki 7
Milan 7
Turin 5
Boardman 4
Rimini 4
Columbus 3
Enschede 3
Lappeenranta 3
Paris 3
Rome 3
Telgate 3
Florence 2
Gatineau 2
Genoa 2
Gujrat 2
Hong Kong 2
Hyderabad 2
Moscow 2
Verona 2
Warsaw 2
Amsterdam 1
Bari 1
Lugano 1
Oderzo 1
Ravenna 1
Seattle 1
Shijiazhuang 1
Tokyo 1
Trento 1
Vienna 1
Totale 163
Nome #
The Palliative Prognostic (PaP) Score without Clinical Evaluation Predicts Early Mortality among Advanced NSCLC Patients Treated with Immunotherapy 29
Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw 26
Hypertransaminasemia in metastatic renal cell carcinoma patients receiving immune-based combinations: a meta-analysis 25
A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy 23
Chromosome 3p gene alterations as biomarkers for immunocombinations in metastatic renal cell carcinoma: A hypothesis-generating analysis 21
Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis 20
Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study 19
The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study 15
Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy 14
TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab 11
Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer 11
Implications of TERT promoter mutations and telomerase activity in solid tumors with a focus on genitourinary cancers 11
Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study 10
Metabolic pseudoprogression in a patient with metastatic KIT exon 11 GIST after 1 month of first-line imatinib: a case report 9
Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis 9
An update on safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma 8
How Do Molecular Classifications Affect the Neoadjuvant Treatment of Muscle-Invasive Urothelial Carcinoma? 7
Tumor growth rate to assess therapy response to immune-based combinations for metastatic renal cell carcinoma 7
Prostate cancer and novel pharmacological treatment options - what's new for 2022? 7
Appropriateness of Mini-Invasive Approaches for Nausea and Vomiting Refractory to Medical Therapy in Palliative Care Setting: A Case Report 5
A prospective study on the early evaluation of response to androgen receptor-targeted agents with 11C-Choline, 68Ga-PSMA, and 18F-FACBC PET in metastatic castration-resistant prostate cancer: a single-center experience 5
What is the risk of hepatotoxicity induced by immune-checkpoint inhibitors and how can we avoid it? 3
Re: Atezolizumab Plus Cabozantinib Versus Cabozantinib Monotherapy for Patients with Renal Cell Carcinoma After Progression with Previous Immune Checkpoint Inhibitor Treatment (CONTACT-03): A Multicentre, Randomised, Open-label, Phase 3 Trial 1
Do we need alternative PD-1 inhibitors for the treatment of renal cell carcinoma? 1
Totale 297
Categoria #
all - tutte 1.756
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.756


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/2023137 0 0 0 0 14 3 8 5 39 11 25 32
2023/2024155 10 18 13 8 14 29 4 15 11 5 18 10
2024/20255 5 0 0 0 0 0 0 0 0 0 0 0
Totale 297